Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureJohn J. V. McMurray
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomized controlled trials.
10.1016/s0140-6736(20)30748-0 · 2020
Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study.
10.1002/ejhf.3267 · 2024
Global variations in heart failure etiology, management, and outcomes.
10.1001/jama.2023.5942 · 2023
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
10.1016/s0140-6736(22)02076-1 · 2022
Improving care for heart failure with reduced ejection fraction—a potential polypill-based strategy.
10.1001/jama.2020.21395 · 2020
Heart failure with reduced ejection fraction polypill implementation strategy in Sri Lanka: a multicenter randomized clinical trial.
Kept as external metadata until matched
Heart failure with reduced ejection fraction polypill implementation strategy in Sri Lanka: design and protocol of a pilot type I hybrid randomised clinical trial.
10.1136/bmjopen-2025-100952 · 2025
Delivering quadruple therapy for heart failure with reduced ejection fraction in a customizable polypill: the COMBO-HF-X pilot randomized trial.
10.1016/j.jchf.2026.103223 · 2026
Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.
10.1038/s41591-026-04504-5 · 2026
Polypill strategy in secondary cardiovascular prevention.
10.1056/nejmoa2208275 · 2022
No additional external references are available.